MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer

Journal of Biological Chemistry

Volumn 290, Issue 10, 2015, Pages 6215-6225

  Zhang, Yang ^a   Geng, Liying ^a   Talmon, Geoffrey ^b   Wang, Jing ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CHEMOTHERAPY; DRUG THERAPY; RNA;

5-FLUOROURACIL (5-FU); COLON CANCER CELLS; COLORECTAL CANCER; DRUG RESISTANCE; ECTOPIC EXPRESSIONS; INDUCED APOPTOSIS; INHIBITION OF TUMOR GROWTH; THERAPEUTIC POTENTIALS;

DISEASES;

FLUOROURACIL; MICRORNA; MICRORNA 520G; MUTANT PROTEIN; OXALIPLATIN; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MIRN520 MICRORNA, HUMAN; PLATINUM COMPLEX; TP53 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HCT116 CELL LINE; METABOLISM; MUTATION; PATHOLOGY;

ANIMALS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICE; MICRORNAS; MUTATION; ORGANOPLATINUM COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924911759     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.620252     Document Type: Article

References (47)

1. Longley, D. B., Harkin, D. P., and Johnston, P. G. (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338
2. Liu, Y.-Y., Han, T.-Y., Giuliano, A. E., and Cabot, M. C. (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15, 719-730
3. Longley, D. B., and Johnston, P. G. (2005) Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292
4. Synold, T. W., Dussault, I., and Forman, B. M. (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7, 584-590
5. Gottesman, M. M. (2002) Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627
6. Du, T., and Zamore, P. D. (2005) microPrimer: the biogenesis and function of microRNA. Development 132, 4645-4652
7. Bartel, D. P. (2009) MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233
8. Hwang, H. W., and Mendell, J. T. (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 94, 776-780
9. Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20
10. Zhang, B., Pan, X., Cobb, G. P., and Anderson, T. A. (2007) MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 302, 1-12
11. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., and Rai, K. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 15524-15529
12. Calin, G. A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., Dell'Aquila, M. L., Alder, H., Rassenti, L., Kipps, T. J., Bullrich, F., Negrini, M., and Croce, C. M. (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. U.S.A. 101, 11755-11760
13. Calin, G. A., and Croce, C. M. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866
14. Calin, G. A., and Croce, C. M. (2006) MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25, 6202-6210
15. Sun, X.-X., Dai, M.-S., and Lu, H. (2007) 5-Fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 282, 8052-8059
16. Miyashita, T., and Reed, J. C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299
17. Kim, C. W., Lu, J. N., Go, S.-I., Jung, J. H., Yi, S. M., Jeong, J.-H., Hah, Y.-S., Han, M. S., Park, J. W., Lee, W. S., and Min, Y. J. (2013) p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Int. J. Oncol. 43, 1495-1502
18. Chakraborty, S., Mazumdar, M., Mukherjee, S., Bhattacharjee, P., Adhikary, A., Manna, A., Chakraborty, S., Khan, P., Sen, A., and Das, T. (2014) Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett. 588, 549-559
19. Metzinger, D. S., Taylor, D. D., and Gercel-Taylor, C. (2006) Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Lett. 236, 302-308
20. Stoklosa, T., Slupianek, A., Datta, M., Nieborowska-Skorska, M., Nowicki, M. O., Koptyra, M., and Skorski, T. (2004) Report BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 3, 1463-1472
21. Boyd, D. D., Levine, A. E., Brattain, D. E., McKnight, M. K., and Brattain, M. G. (1988) Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res. 48, 2469-2474
22. Valeri, N., Gasparini, P., Braconi, C., Paone, A., Lovat, F., Fabbri, M., Sumani, K. M., Alder, H., Amadori, D., and Patel, T. (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. U.S.A. 107, 21098-21103
23. Geng, L., Chaudhuri, A., Talmon, G., Wisecarver, J. L., Are, C., Brattain, M., and Wang, J. (2014) MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 33, 5332-5340
24. Jun, L., Haiping, Z., and Beibei, Y. (2009) Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med. Wkly.139, 724-728
25. Kim, S.-H., Kwon, H.-C., Oh, S. Y., Lee, D. M., Lee, S., Lee, J.-H., Roh, M.-S., Kim, D.-C., Park, K.-J., Choi, H.-J., and Kim H.-J. (2009) Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase π for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 32, 38-43
26. Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., and Bartel, D. P. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91-105
27. Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., and Stoffel, M. (2005) Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500
28. Betel, D., Koppal, A., Agius, P., Sander, C., and Leslie, C. (2010) Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11, R90
29. Galmarini, C. M., Bouchet, B. P., Audoynaud, C., Lamblot, C., Falette, N., Bertholon, J., Wang, Q., Beghin, A., Dumontet, C., and Puisieux, A. (2006) A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int. J. Cancer 119, 60-66
30. Abukhdeir, A. M., Vitolo, M. I., Argani, P., De Marzo, A. M., Karakas, B., Konishi, H., Gustin, J. P., Lauring, J., Garay, J. P., and Pendleton, C. (2008) Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc. Natl. Acad. Sci. U.S.A. 105, 288-293
31. Aneja, R., Ghaleb, A. M., Zhou, J., Yang, V. W., and Joshi, H. C. (2007) p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 67, 3862-3870
32. Koster, R., di Pietro, A., Timmer-Bosscha, H., Gibcus, J. H., van den Berg, A., Suurmeijer, A. J., Bischoff, R., Gietema, J. A., and de Jong, S. (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J. Clin. Invest. 120, 3594-3605
33. Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S., and Gabrilovich, D. I. (2004) Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103, 3503-3510
34. Cip1 confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Lett. 292, 133-139
35. Gayet, J., Zhou, X.-P., Duval, A., Rolland, S., Hoang, J.-M., Cottu, P., and Hamelin, R. (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20, 5025-5032
36. Lim, H. K., Bae, W., Lee, H.-S., and Jung, J. (2014) Anticancer activity of marine sponge Hyrtios sp. extract in human colorectal carcinoma RKO cells with different p53 status. BioMed Res. Int. 27, 413575
37. Grassilli, E., Narloch, R., Federzoni, E., Ianzano, L., Pisano, F., Giovannoni, R., Romano, G., Masiero, L., Leone, B. E., and Bonin, S. (2013) Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin. Cancer Res. 19, 3820-3831
38. Moertel, C. G. (1978) Chemotherapy of gastrointestinal cancer. N. Engl. J. Med. 299, 1049-1052
39. Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., and Wils, J. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352, 1407-1412
40. Chowdhury, S., Howell, G. M., Rajput, A., Teggart, C. A., Brattain, L. E., Weber, H. R., Chowdhury, A., and Brattain, M. G. (2011) Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS ONE 6, e19335
41. Wang, J., Yang, L., Yang, J., Kuropatwinski, K., Wang, W., Liu, X.-Q., Hauser, J., and Brattain, M. G. (2008) Transforming growth factor β induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 68, 3152-3160
42. Yang, J., Ouyang, J., Ouyang, L., Ouyang, L., and Chen, Y. (2013) Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells. Oncol. Res. 21, 43-50
43. Slichenmyer, W. J., Nelson, W. G., Slebos, R. J., and Kastan, M. B. (1993) Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53, 4164-4168
44. Kang, K. H., Kim, W. H., and Choi, K. H. (1999) p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp. Cell Res. 253, 403-412
45. Borralho, P. M., Kren, B. T., Castro, R. E., Moreira da Silva, I. B., Steer, C. J., and Rodrigues, C. M. (2009) MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 276, 6689-6700
46. Fearon, E. R., and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759-767
47. Krell, J., Frampton, A. E., Colombo, T., Gall, T. M., De Giorgio, A., Harding, V., Stebbing, J., and Castellano, L. (2013) The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics 5, 417-428